In this case, I would disagree. Pharma mergers are usually intended to secure the sales force in the new company. UEEC doesn’t have any type of sales force or infrastructure to buy. It’s only HemoStyp that the acquirer will want. I think this will be an all cash buyout. Our market cap is only $100mm or so. We’re “small potatoes” in the scheme of things to the big guys. IMO